Modulation of mitochondrial protein kinase C isozymes: A new therapeutic frontier?

Tiffany Nguyen, Mourad Ogbi, Dehuang Guo, John A. Johnson

Research output: Contribution to journalReview articlepeer-review

7 Scopus citations


Alterations in protein kinase C (PKC) isozymes and mitochondrial functions such as oxidative phosphorylation (OXPHOS) and apoptosis have each been implicated in human diseases. However, relatively little is currently understood regarding the physiologic roles of individual PKC isozymes or their substrates for phosphorylation in mitochondria. Recent advances in mitochondrial localization of PKC isozymes and methods of PKC isozyme-selective inhibition have made possible a more focused pursuit of these relationships. Studies of PKC isozyme involvement in areas such as mitochondrial ROS production, antioxidant defense, energetics, and apoptosis are now possible and hold the potential to provide promising pharmaceuticals for therapies against cardiovascular, diabetic, cancer and other diseases. The purpose of this review is to present the current state of knowledge illustrating a link between PKC isozymes, mitochondria and human disease. Novel strategies for PKC isozyme-selective inhibition will also be discussed with an emphasis on the rational targeting of mitochondrial PKC isozymes in research and clinical settings.

Original languageEnglish (US)
Pages (from-to)143-159
Number of pages17
JournalCurrent Enzyme Inhibition
Issue number2
StatePublished - May 2007


  • Antisense
  • Apoptosis
  • Disease
  • Energetics
  • Mitochondria
  • Protein kinase C isozyme-selective inhibition
  • Pseudosubstrate
  • ROS
  • Translocation inhibitors

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Medicine
  • Drug Discovery


Dive into the research topics of 'Modulation of mitochondrial protein kinase C isozymes: A new therapeutic frontier?'. Together they form a unique fingerprint.

Cite this